Pathstone Holdings’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11M Buy
19,494
+691
+4% +$443K 0.04% 317
2025
Q4
$12.7M Sell
18,803
-1,031
-5% -$702K 0.05% 260
2025
Q3
$12.7M Buy
19,834
+350
+2% +$212K 0.05% 268
2025
Q2
$10.5M Sell
19,484
-1,883
-9% -$900K 0.04% 313
2025
Q1
$8.98M Buy
21,367
+311
+1% +$135K 0.04% 375
2024
Q4
$8.71M Sell
21,056
-2,604
-11% -$1.14M 0.04% 360
2024
Q3
$12M Sell
23,660
-1,440
-6% -$700K 0.05% 268
2024
Q2
$12.2M Buy
25,100
+69
+0.3% +$34.6K 0.06% 256
2024
Q1
$13.5M Buy
25,031
+7,612
+44% +$4.16M 0.06% 229
2023
Q4
$9.67M Buy
+17,419
New +$8.18M 0.05% 263

Other funds holding IDXX

Pathstone Holdings's IDXX Position: Q1 2026 in Review

Pathstone Holdings increased its Idexx Laboratories (IDXX) stake by 3.7% in Q1 2026, buying an estimated $443K and bringing the position to 19,494 shares worth $11M. The position accounts for 0.04% of the portfolio, ranked #317.

Pathstone Holdings first reported a position in IDXX in Q4 2023 and has held it in 10 quarters since. The position peaked at $13.5M in Q1 2024. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Pathstone Holdings held 19,494 shares of Idexx Laboratories worth $11M as of Q1 2026.
  • Pathstone Holdings bought 691 Idexx Laboratories shares in Q1 2026, an estimated $443K.
  • Idexx Laboratories made up 0.04% of Pathstone Holdings's portfolio in Q1 2026, its #317 holding.
  • Pathstone Holdings first reported a position in Idexx Laboratories in Q4 2023 and has held it in 10 quarters since.
  • Pathstone Holdings's Idexx Laboratories position peaked at $13.5M in Q1 2024.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.